Tag: DurAVR THV
Anteris marks first successful implantation of DurAVR THV heart valve
ASX-listed biotechnology company Anteris Technologies has announced the successful use of its DurAVR THV biomimetic valve in a valve-in-valve (ViV) procedure.Â
Anteris awarded utility patent for novel transcatheter heart valve replacement
Australian biotechnology company Anteris Technologies announced that the US Patent and Trademark Office has issued another utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
Driving the future of smart energy: GridBeyond and ABB unveil new white paper on battery storage innovation
As industries adopt cleaner, more intelligent energy solutions, the ability to manage, store, and trade energy efficiently is increasingly vital to sustaining a competitive edge.
